How Much Obesity and Diabetes Do Impair Male Fertility?

2021 ◽  
Author(s):  
Shima Abbasihormozi ◽  
Azam Kohkan ◽  
Abdolhossein Shahverdi ◽  
Amir Parhizkar ◽  
Samira Vesali
Keyword(s):  
Semen Analysis ◽  
High Sensitivity ◽  
Reproductive Age ◽  
Sex Hormone Binding Globulin ◽  
Total Testosterone ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Obesity And Diabetes ◽  
Control Serum ◽  
Significant Difference

Abstract BackgroundSubfertility in obese and diabetic men during the reproductive age is evident, but the mechanisms by which obesity and diabetes mellitus cause male infertility are not entirely understood. The current study aimed to evaluate the effects and potential mechanisms of obesity and diabetes on male fertilityMethodsWe enrolled control=40, obese=40, Lean-DM=35, and Obese-DM=35 individuals. The obesity-associated markers, diabetic markers, hormonal and lipid profile, inflammatory indices, and semen analysis were assessed in four experimental groups.ResultsOur finding showed that diabetic markers were significantly increased in two diabetic groups, while obesity indices were markedly increased in two obese groups. Conventional sperm parameters were significantly lower in three groups compared with the control. Serum levels of total testosterone and sex hormone-binding globulin were significantly lower in men with obesity and DM compared with the control. There was a significant difference in the concentration of high-sensitivity C-reactive protein among four experimental groups. Moreover, serum leptin was significantly increased in obese DM, lean DM, and obese groups. Serum insulin levels had a positive correlation with metabolic-associated indices and high-sensitivity C-reactive protein levels, whereas it had a negative correlation with count, motility, and morphology. ConclusionsOur findings showed the metabolic changes, hormonal dysfunction and inflammatory disturbance might be suspected mechanisms of subfertility in obese and diabetic subfertile men.

scholarly journals High Sensitivity CReactive Protein (hsCRP) Level on Premature Rupture of Membrane (PROM) at Term Pregnancy

2017 ◽  
pp. 12-15
Author(s):  
Meily Manoppo ◽  
Hermie MM Tendean ◽  
Joice MM Sondakh
Keyword(s):  
High Sensitivity ◽  
C Reactive Protein ◽  
Term Pregnancy ◽  
Premature Rupture ◽  
Cross Sectional ◽  
Reactive Protein ◽  
Significant Difference ◽  
Hs Crp ◽  
Cross Sectional Design ◽  
Parametric Statistical Test

Objective: To compare the level of high sensitivity C-Reactive Protein (hs-CRP) on patients with premature rupture of membranes (PROM) at term pregnancy. Methods: The study was cross-sectional design. The data collection included age, parity, gestational age, birth weight, and APGAR score on 28 pregnant women at term pregnancy consisting of 14 subjects of Premature Rupture of Membrane (PROM) less than 12 hours and the remaining one was equal or more than 12 hours. We took blood samples from the subjects for the examination of hs-CRP level. Data were analyzed using non-parametric statistical test and processed using Statistical Package for Social Sciences (SPSS) version 20. Results: The mean hs-CRP level on PROM <12-hour and 12-hour group was 12.9 and 17.8 mg/l. There was not significant difference on hs-CRP level between both of group at term pregnancy (p=0.734). Conclusion: The level of hs-CRP does not have association with the incidence of PROM. [Indones J Obstet Gynecol 2017; 5-1: 12-15] Keywords: high sensitivity C-Reactive Protein, premature ruptures of membranes, term pregnancy

Abstract 346: Platelet Reactivity to Aspirin and Clopidogrel in Patients with Acute ST Elevation Myocardial Infarction and its Correlation with High Sensitivity C- Reactive Protein

2013 ◽  
Vol 33 (suppl_1) ◽  
Author(s):  
Archana Rajdev ◽  
Oana Penciu ◽  
Jacqueline Bradley ◽  
Cristina Mihu ◽  
Alan Siqueros ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Platelet Reactivity ◽  
High Sensitivity ◽  
St Elevation Myocardial Infarction ◽  
Diabetic Patients ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Significant Difference ◽  
St Elevation ◽  
Hs Crp

INTRODUCTION Implantation of bare metal or drug eluting stents supported by dual antiplatelet therapy (DAPT) is standard treatment for the management of patients with ST elevation myocardial infarction (STEMI). Individual response to aspirin and clopidogrel is heterogeneous, and decreased response is associated with thrombotic events following stenting. We postulated that systemic inflammation at the time of STEMI would diminish responsiveness to DAPT. The aim of this study is to evaluate the correlation between elevated high-sensitivity C-reactive protein (hs-CRP) as a marker of inflammation and decreased platelet sensitivity to DAPT in STEMI. METHODS We recruited patients with STEMI undergoing percutaneous coronary intervention (PCI) who received oral clopidogrel 600 mg loading dose followed by 75 mg daily maintenance dose and aspirin 325 mg daily. Platelet reactivity and hs-CRP were measured within 72 hours of PCI and at 6 weeks. For patients receiving eptifibatide, blood samples were taken 48 hours after discontinuation. Platelet reactivity was assessed using the VerifyNow platelet function analyzer. A cut-off value of 208 platelet reaction units (PRU) was used to define high on-clopidogrel platelet reactivity (HCPR) and a value of 454 aspirin reaction units (ARU) was used to define high on-aspirin platelet reactivity (HAPR). RESULTS In 20 patients aged 31 to 85, in hospital and 6 weeks after STEMI, hs-CRP was 6.7 (SD 4.0) and 2.6 (SD 3.2) respectively, p< 0.01. Changes in ARU from 408.3 (SD 54.3) to 425.2 (SD 68.2) and PRU from 157.8 (SD 74.7) to 164.2 (SD 75) were not statistically significant. 2 patients had HAPR in hospital; 1 became sensitive at follow up. 2 patients developed HAPR and HCPR. We saw a trend towards higher PRU in diabetic patients and those prescribed statins. CONCLUSIONS Although we found a significant difference in hs-CRP levels between the first and second time point, no significant difference was found in on-aspirin and on-clopidogrel platelet reactivity between the time points.Thus, in this small series, the acute inflammatory state associated with STEMI did not appear to influence the on-DAPT reactivity at the dosages used. Trends among those with diabetics and prescribed statins will be discussed

scholarly journals Association between weekend catch-up sleep and high-sensitivity C-reactive protein levels in adults: a population-based study

SLEEP ◽  
2020 ◽  
Vol 43 (8) ◽  
Author(s):  
Kyu-Man Han ◽  
Heon-Jeong Lee ◽  
Leen Kim ◽  
Ho-Kyoung Yoon
Keyword(s):  
Sleep Duration ◽  
High Sensitivity ◽  
Low Grade ◽  
C Reactive Protein ◽  
Hscrp Level ◽  
Obese People ◽  
Cross Sectional ◽  
Reactive Protein ◽  
Significant Difference ◽  
Catch Up

Abstract Study Objectives To investigate the association between weekend catch-up sleep (WCS) and the levels of high-sensitivity C-reactive protein (hsCRP)—a serum inflammatory maker—in adults Methods Data of 5,506 adults aged 19 years or older were obtained from the nationwide cross-sectional Korea National Health and Nutrition Examination Surveys conducted in 2016. Serum hsCRP level, weekday and weekend sleep durations, and sociodemographic and health-related characteristics were assessed. Participants whose weekend sleep duration was more than 1 h longer than their weekday sleep duration were included in the WCS group. hsCRP level was categorized into quartiles (i.e. highest, middle-high, middle-low, and lowest). Obesity was defined by body mass index ≥ 25.0 kg/m2. Results The WCS group included 1,901 participants (34.5%). In the logistic regression analysis controlling for all variables, adults in the WCS group were significantly less likely to show the highest hsCRP level (versus the lowest level) compared with those without WCS in the complete sample (adjusted odds ratio = 0.795, 95% confidence interval [CI] = 0.662 to 0.955). In a subgroup analysis, this association was significant only for those with weekday sleep duration of 6 h or lower. Longer WCS (≥3 h) was not associated with hsCRP levels. Non-obese people with WCS demonstrated a lower risk for high hsCRP levels, while there was no significant difference in obese people with WCS. Conclusions Our findings indicate that WCS may be beneficial for low-grade systemic inflammation in adults, particularly among those with shorter weekday sleep durations. WCS may also interact with obesity.

scholarly journals Controlled Clinical Trial Effect of Noni Fruit Extract (Morinda citrifolia) Toward Overactive Bladder Women through Observation of High-Sensitivity C-reactive Protein in Urine Levels

2020 ◽  
Vol 8 (A) ◽  
pp. 706-710
Author(s):  
Edy Ardiansyah ◽  
M. F. G. Siregar ◽  
R. A. Ganie ◽  
I. B. Utra
Keyword(s):  
Oxidative Stress ◽  
High Sensitivity ◽  
Morinda Citrifolia ◽  
C Reactive Protein ◽  
Urine Level ◽  
Fruit Extract ◽  
Reactive Protein ◽  
Significant Difference ◽  
Hs Crp ◽  
Urine Levels

BACKGROUND: The prevalence of overactive bladder (OAB) appears to increase with age (aging), and free radicals most contribute to an increase in the aging process. But now, some researchers have found the efficacy of Morinda citrifolia in inhibiting the oxidative stress process so that it is expected to be beneficial for the treatment of OAB. AIM: The aim of this study was to find out the effect of M. citrifolia extract on overactive women bladder (OAB) through observation of high-sensitivity C-reactive protein (hs-CRP) urine level. METHODS: This research is an experimental study using double-blind randomized controlled trial design conducted at General Hospital H. Adam Malik Medan, USU Pharmacy Laboratory for extraction of noni fruit (M. citrifolia) and the Integrated Laboratory of Biochemical-Biomolecular USU Faculty of Medicine for the examination of hs-CRP urine levels. A t-dependent test is performed if data distribution is normally distributed or if not normally distributed, the median values are compared with the Mann–Whitney U-test. The effect of noni in hs-CRP levels performed by wilcoxon signed-Ranks Test. The statistical significance test with CI 95% and significant difference value p<0,05. RESULTS: These results indicate that the noni fruit extract has weak antioxidant activity (IC50 >150 ppm). From the statistical analysis, a significant difference (p < 0.05) was obtained in hs-CRP urine level after compared to before treatment. These results indicate that after treatment, there was an improvement in the degree of OAB symptom scores in Group A and Group B. CONCLUSIONS: Noni fruit extract (M. citrifolia) is proven to be able to inhibit oxidative stress in urothelium through observation of hs-CRP urine levels in overactive women bladder (OAB).  

Abstract 13654: Gemcabene Monotherapy and in Combination With Atorvastatin Lowers High Sensitivity C-Reactive Protein (hsCRP) in a Phase 2 Clinical Trial

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Evan A Stein ◽  
Rebecca Bakker-Arkenma ◽  
Margaret M McShane ◽  
Mina P Sooch ◽  
Charles L Bisgaier
Keyword(s):  
Vascular Inflammation ◽  
Dose Range ◽  
High Sensitivity ◽  
Lipid Lowering ◽  
Phase 2 ◽  
C Reactive Protein ◽  
Double Blind ◽  
Reactive Protein ◽  
Significant Difference ◽  
Phase 2 Clinical Trial

Background: It is well established that inflammation plays a key role the progression of atherosclerosis and that serum high sensitivity c-reactive protein (hsCRP), may be a good marker of the degree of underlying vascular inflammation. Thus hsCRP has been recognized as a predictor of cardiovascular risk and lipid lowering drugs, such as statins, which also result in a reduction of hsCRP may be more likely to reduce cardiovascular events. Gemcabene is an inhibitor of hepatic cholesterol, triglyceride, and apoC-III synthesis resulting in decreased assembly of VLDL and enhances the systemic clearance of VLDL and its subsequently production of remodeled lipoproteins including LDL. Study Design and Results: In an 8-week double blind randomized, placebo-controlled, dose-ranging, efficacy and safety Phase 2 study, gemcabene 300, 600 and 900 mg/day administered as monotherapy or in combination with atorvastatin 10, 20 and 80 mg/day resulted in a significant and dose dependent reduction of LDL-C (Study 4141001). A secondary objective of this study was to evaluate the modulation of hsCRP by gemcabene. Of 277 patients randomized, 250 (90%) completed the study. Baseline mean LDL-C was 174.7mg/dL, and median hsCRP = 2.5 mg/L. The median % reduction in hsCRP with Gemcabene 300, 600 and 900 mg monotherapy was 25.8%, 41.5% and 35.3% respectively compared with 9.4% for placebo. The rank-transformed data showed significant difference favoring gemcabene over placebo in the 600 and 900 mg groups (p=0.0070 and p =0.0018, respectively). Co-administration of 300, 600, and 900 mg gemcabene with atorvastatin aggregated over the dose range showed decreases in hsCRP beyond atorvastatin monotherapy (which ranged from 27-41%) by an additional 16% (p=0.0237), 23% (p=0.0017) and 28% (p=0.0001), respectively. Conclusions: Gemcabene significantly lowered hsCRP alone and on top of statins in hypercholesterolemic patients.

scholarly journals To study the correlation of high sensitivity C reactive protein levels with asthma control in children

2016 ◽  
Vol 4 (1) ◽  
pp. 145
Author(s):  
Nithiyanantham Ramakrishnan ◽  
Shobhana Sivathanu ◽  
Sowmya Sampath ◽  
Suresh David JH ◽  
Thuthi Mohan
Keyword(s):  
Asthma Control ◽  
Inhaled Corticosteroids ◽  
Surrogate Marker ◽  
Persistent Asthma ◽  
Inverse Correlation ◽  
High Sensitivity ◽  
Mean Value ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Significant Difference

Background: Childhood asthma appears to be increasing in prevalence despite advancements in the care of asthma. In asthma, local as well as systemic inflammation contributes to the pathogenesis. Thus successful management depends on controlling this inflammation by appropriate doses of inhaled corticosteroids. High sensitivity C reactive protein (hsCRP) is an easily measurable marker of inflammation and its level can be used as a diagnostic tool in assessing control of asthma. The objective of this study was study the correlation of serum hsCRP levels with asthma control in childrenMethods: It is an observational study conducted in the Pediatric asthma clinic of a Government Medical College in south India. The study population consisted of 75 asthmatic children aged 5-15 years. Children with persistent asthma were classified into three groups based on GINA guidelines. Serum hsCRP levels were measured in all the three groups.Results: Among the 75 children 33% belonged to controlled group, 35% to uncontrolled group and 33% to partly controlled group. There was a significant difference in hsCRP levels between controlled and uncontrolled groups. The mean value of hsCRP in controlled group was 0.93±1.3 mg/L whereas in the uncontrolled group it was 2.73±2.46 mg/L. Higher levels of hsCRP were found in the uncontrolled asthma group.Conclusions: There is an inverse correlation between hsCRP levels and asthma control in children. High hsCRP levels have a potential to be used as a surrogate marker for poor control of asthma and can thus be used as a guide for adjustment of dosage of inhaled corticosteroids. 

Activity of systemic juvenile idiopathic arthritis in children immunized with pneumococcal 13-valent conjugate vaccine: prospective cohort study

2020 ◽  
Vol 15 (5) ◽  
pp. 40-50
Author(s):  
D.D. Vankova ◽  
◽  
E.I. Alekseeva ◽  
T.M. Dvoryakovskaya ◽  
R.V. Denisova ◽  
...  
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Disease Activity ◽  
Conjugate Vaccine ◽  
Systemic Juvenile Idiopathic Arthritis ◽  
High Sensitivity ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Significant Difference ◽  
Hs Crp ◽  
Active Disease

Evaluation of the safety profile of vaccines in patients with rheumatic diseases requires an assessment of their impact on disease activity. The effect of antipneumococcal vaccination on the activity of systemic juvenile idiopathic arthritis (sJIA) has not been studied so far. Objective. To evaluate the dynamics of sJIA activity after immunization with pneumococcal 13-valent conjugate vaccine (PCV13) of patients receiving biologicals. Patients and methods. This study included patients with sJIA in remission or active disease receiving biologicals during inpatient treatment and vaccinated with PCV13. To evaluate the effect of immunization on sJIA activity, we measured serum levels of high-sensitivity C-reactive protein (hs-CRP) and calprotectin. In addition to that, we assessed the number of new cases, when concentration of these markers was above the upper limit (UL) 4 weeks after PCV13 administration. Results. In 18 out of 53 patients in remission (34%) and 3 out of 25 patients with active sJIA (12%), hs-CRP levels were undetectable (0.1 mg/L) at both time-points (baseline and after 4 weeks). Among those with detectable hs-CRP levels in at least one time-point 4 weeks after vaccination, patients in remission (n = 35) had no significant changes in hs-CRP (median -0.17 mg/mL; 95% CI -0.84…0.41), whereas patients with active sJIA (n = 22) demonstrated a 3-fold decrease in hs-CRP level (median -0.94 mg/mL (95% CI -3.93…0.05). We observed no significant difference in calprotectin levels in the groups. Concentration of hs-CRP above the UL 4 weeks after vaccination was detected in 2 out of 53 sJIA patients in remission (4%) and none of the patients with active sJIA. Сoncentration of calprotectin above the UL 4 weeks after vaccination was detected in 8 out 53 (15%) and 5 out 25 (20%) sJIA patients in remission and with active disease, respectively. Conclusion. Vaccination against pneumococcal infection in patients with sJIA led to an increase in the level of highly sensitive laboratory markers of sJIA activity in 4–20% of patients. Key words: disease activity, safety, high-sensitivity C-reactive protein, biological drugs, calprotectin, juvenile idiopathic arthritis, pneumococcal 13-valent conjugate vaccine

Sign in / Sign up

Export Citation Format

Share Document